Diabetic Nephropathy: Pharmacological and Emerging Approches

Abstract

Diabetic nephropathy is diagnosed by persistent albuminuria on two or more occasions, separated at least by three months on early morning urine samples. Persistent albuminuria is greater than 300 mg over 24 hours or greater than 200 micrograms per minute. Moderately increased albuminuria is when the urine albumin excretion rate is between 30 to 300 mg over 24 hours and is a marker of early DN. It is critical to exclude a urinary tract infection as the cause of albuminuria by a urinalysis. Proteinuria is the hallmark of diabetic nephropathy. The absence of retinopathy makes diabetic nephropathy less likely in T1DM. The scenario is more difficult in T2DM than with T1DM. The exact time of the onset of T2DM is unclear in most patients. History and physical exam play a crucial role in diagnosing diabetic nephropathy in T2DM. Diabetic nephropathy (DN) is a significant microvascular complication of diabetes mellitus, affecting 30-40% of diabetic patients and serving as the leading cause of end-stage renal disease (ESRD) worldwide. DN is characterized by progressive kidney damage due to chronic hyperglycemia, oxidative stress, and hemodynamic abnormalities, resulting in glomerular hypertrophy, mesangial expansion, podocyte loss, and tubulointerstitial fibrosis. The pathogenesis of DN involves the activation of multiple pathways, including the polyol pathway, advanced glycation end-products (AGEs) formation, protein kinase C (PKC) activation, and renin- angiotensin-aldosterone system (RAAS) overactivity. These mechanisms collectively promote inflammation, oxidative stress, and fibrosis, leading to impaired kidney function and proteinuria. While conventional treatments such as RAAS blockade and glycemic control remain essential, emerging therapies offer new hope for better management. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, nonsteroidal mineralocorticoid receptor antagonists, and glucagon-like peptide-1 receptor agonists have shown promising reno-protective effects. Novel therapies, including endothelin receptor antagonists, Bardoxolone methyl, gene therapy, andstem cell-based interventions, target key molecular pathways to halt or reverse disease progression. This review highlights the pathophysiology, current pharmacological treatments, and emerging approaches, emphasizing the importance of early diagnosis and novel interventions in improving renal outcomes for diabetic patients.

Key words: Diabetic nephropathy, diabetes mellitus, RAAS, SGLT-2 inhibitors, etc..